Q3 EPS Estimate for Core Laboratories Lowered by Analyst

Key Points

• Zacks Research cut its Q3 2027 EPS estimate for Core Laboratories to $0.27 from $0.32, while the consensus full-year EPS is $0.57 and Zacks' FY2027 forecast is $1.06.
• Core Laboratories recently beat the quarter with $0.21 EPS (vs. $0.20 expected) and $138.3M revenue (up 7% YoY), and set Q1 2026 guidance of $0.110–$0.150 EPS.
• The stock carries an average "Hold" rating with a consensus price target of $12.50, while shares recently traded around $17.06 and the dividend yield is roughly 0.2%.

Core Laboratories Inc. (NYSE:CLB - Free Report) - Equities research analysts at Zacks Research reduced their Q3 2027 earnings per share (EPS) estimates for Core Laboratories in a report issued on Thursday, April 23rd. Zacks Research analyst Team now forecasts that the oil and gas company will post earnings per share of $0.27 for the quarter, down from their previous forecast of $0.32. The consensus estimate for Core Laboratories' current full-year earnings is $0.57 per share. Zacks Research also issued estimates for Core Laboratories' FY2027 earnings at $1.06 EPS.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its earnings results on Wednesday, February 4th. The oil and gas company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.01. The firm had revenue of $138.26 million for the quarter, compared to the consensus estimate of $130.40 million. Core Laboratories had a net margin of 6.04% and a return on equity of 12.18%. The business's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 earnings per share. Core Laboratories has set its Q1 2026 guidance at 0.110-0.150 EPS.

Separately, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Core Laboratories in a research report on Friday, March 27th. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $12.50.

Core Laboratories Price Performance

CLB opened at $17.06 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.51 and a current ratio of 2.02. Core Laboratories has a 52-week low of $9.72 and a 52-week high of $20.36. The stock has a market capitalization of $785.75 million, a P/E ratio of 25.47, a P/E/G ratio of 3.21 and a beta of 1.15. The company's 50-day simple moving average is $16.85 and its two-hundred day simple moving average is $16.50.

Core Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 9th. Investors of record on Monday, February 16th were issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend was Friday, February 13th. Core Laboratories's dividend payout ratio (DPR) is currently 5.97%.

Hedge Funds Weigh In On Core Laboratories

A number of hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd bought a new stake in shares of Core Laboratories during the fourth quarter valued at approximately $34,000. CWM LLC increased its holdings in Core Laboratories by 36.1% in the 4th quarter. CWM LLC now owns 2,516 shares of the oil and gas company's stock valued at $40,000 after acquiring an additional 668 shares during the last quarter. Quarry LP increased its holdings in Core Laboratories by 118.1% in the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company's stock valued at $36,000 after acquiring an additional 1,599 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Core Laboratories by 124.7% in the 4th quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company's stock valued at $51,000 after acquiring an additional 1,763 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Core Laboratories by 73.3% during the fourth quarter. GAMMA Investing LLC now owns 5,157 shares of the oil and gas company's stock valued at $83,000 after buying an additional 2,181 shares during the last quarter. Institutional investors own 97.81% of the company's stock.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company's portfolio spans two primary service lines: reservoir description and production enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.